Supernus Pharmaceuticals (SUPN) Non Operating Income (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Non Operating Income data on file, last reported at $2.0 million in Q4 2025.

• On a quarterly basis, Non Operating Income fell 59.35% year-over-year to $2.0 million in Q4 2025; TTM through Dec 2025 was $13.3 million, a 18.21% decrease from a year earlier, with the FY2025 full-year figure at $13.3 million, down 18.21% from the prior year.
• Non Operating Income for Q4 2025 stood at $2.0 million, down from $2.3 million in the prior quarter.
• Over the last five years, Non Operating Income for SUPN reached as high as $12.8 million in Q1 2022 and fell as low as -$3.6 million in Q3 2021.
• Historically, Non Operating Income has averaged $2.3 million across 5 years, with a median of $2.0 million in 2025.
• Across the five-year window, Non Operating Income plunged 10486.36% in 2021 and soared 2190.91% in 2023, its largest moves.
• Year by year, Non Operating Income stood at -$3.6 million in 2021, then surged by 122.12% to $806000.0 in 2022, then surged by 146.4% to $2.0 million in 2023, then surged by 150.6% to $5.0 million in 2024, then sank by 59.35% to $2.0 million in 2025.
• Per Business Quant data, the three most recent Non Operating Income figures were $2.0 million in Q4 2025, $2.3 million in Q3 2025, and $4.5 million in Q2 2025.